Biotech Growth Trust PLCLSE: BIOG

Biotech Growth Trust: Transaction in Own Shares

· Issued by Biotech Growth Trust PLC via PR Newswire

Summary by 6ix AI

The Biotech Growth Trust PLC bought 125,000 of its ordinary shares of 25p each on October 9, 2026, at a price of 1418.67 pence per share, to be cancelled.

Key details

  • After the purchase, the company has 18,639,477 ordinary shares in issue, which is also its total number of voting rights.
  • The company holds no ordinary shares in treasury (shares bought back and held rather than cancelled).
  • The buyback uses authority granted at the company's Annual General Meeting on July 16, 2026, to buy back up to an aggregate maximum of 2,864,231 of its own shares.
  • Shareholders may use the 18,639,477 figure to work out whether they must report their holding, or a change in it, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/transaction-in-own-shares-1289

For immediate release

9 October 2026

THE BIOTECH GROWTH TRUST PLC

(the "Company")

MARKET PURCHASE OF COMPANY'S OWN SHARES

Notification is given, pursuant to the authority granted at the Annual General Meeting of the Company held on 16 July 2026 to make market purchases of the Company's own shares up to an aggregate maximum of 2,864,231 that a market total of 125,000 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 1418.67 pence per share.

Following this transaction, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company 18,639,477. The Company does not currently hold any Ordinary shares in treasury.

The figure of 18,639,477 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For and on behalf of

Frostrow Capital LLP

Company Secretary

For further information, please contact:

Katherine Manson

Frostrow Capital LLP

Tel: 020 3709 8734


Biotech Growth Trust PLC on 6ix

Earlier from Biotech Growth Trust

Later from Biotech Growth Trust

All Biotech Growth Trust news releases